Gilteritinib is an anticancer drug approved for treating adults with relapsed or refractory acute myeloid leukemia (AML).

Gilteritinib is an anticancer drug approved for treating adults with relapsed or refractory acute myeloid leukemia (AML) with a specific gene (FLT3) mutation.
AML is a type of blood cancer, in which the count of white blood cells increases significantly. 

Hypersensitivity to Gilteritinib or any of the excipients.

It is available as a 40mg tablet.
The initial dose for adults is 120mg once a day orally with or without food.

If a dose of Gilteritinib is missed or not taken at the routine time, it should be taken as soon as possible on the same day.
Two doses should be taken in 12 hours.

Do not break or crush Gilteritinib tablets. They should be taken at about the same time each day.

1. General: Fever, edema, fatigue, eye disorders, joint pains, rash
2. Gastrointestinal: Nausea, vomiting, constipation, diarrhea
3. Nervous system: Dizziness, headache
4. Respiratory: Cough, shortness of breath
5. Vascular: Hypotension
6. Raised liver enzymes, renal impairment

Caution is advised for the following group of patients:
1.Posterior reversible encephalopathy syndrome
2.Prolonged QT Interval (an ECG abnormality)
3.Low potassium (Hypokalemia) or low magnesium ( hypomagnesemia)
4.Inflammation of the pancreas (pancreatitis)
5.Embryo-Fetal Toxicity: Giteritinib can cause fetal harm when administered to a pregnant woman. Women should use proper contraception in this case.

Gilteritinib will interact with these drugs:
1.Escitalopram
2.Fluoxetine
3.Sertraline

Store Gilteritinib tablets at 20ºC to 25ºC.
Keep in the original container until dispensed.
Protect from light, moisture, and humidity.